

Tandem Pharmacy Track at the 2024 Tandem Meetings - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Alexis Kuhn, PharmD, BCOP	Faculty	1. Jazz Pharmaceuticals, Sanofi Genzyme, Inc.	1. Advisory Board	<p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning</p> <p>The following relationships were mitigated by:</p> <ul style="list-style-type: none"> <li>• Jazz Pharmaceuticals ending in December 2022.</li> <li>• Sanofi Genzyme, Inc. ending in April 2023.</li> </ul>
Amanda Olson, MD	Faculty	No relevant financial disclosures	N/A	N/A
Amir Ali, PharmD, BCOP	Planning Committee Member	1. Sanofi	1. Non-CE Speakers Bureau	All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair
Andrew Lin, PharmD, BCOP	Faculty	1. EUSA Pharma, Incyte, Medexus	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning
Ashley Smeaton, MHA	TFF Staff	No relevant financial disclosures	N/A	N/A
Breana Goscicki, PharmD, BCPPS	Planning Committee Member, Faculty	No relevant financial disclosures	N/A	N/A
Breanna Taylor, PharmD, BCOP	Planning Committee Member	No relevant financial disclosures	N/A	N/A

Tandem Pharmacy Track at the 2024 Tandem Meetings - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Brijesh Gautama, MPharm (Hons), PGDip	Faculty	1. Roche Products, Ltd. 2. Gilead Sciences, Ltd. 3. CSL Behring, Ltd., Gilead Sciences, Ltd., Janssen-Cilag Ltd.	1. Non-CE Consulting 2. Non-CE Speakers Bureau 3. Sponsorship of registration fees, travel, and accommodation expenses	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning  The following relationships were mitigated by: <ul style="list-style-type: none"> <li>• Non-CE consulting relationship with Roche Products, Ltd. ending in June 2022.</li> <li>• Non-CE speakers bureau relationship with Gilead Sciences, Ltd. ending in June 2023.</li> <li>• Sponsorship relationship with Gilead Sciences, Ltd. and Janssen-Cilag, Ltd. ending in November 2023.</li> <li>• Sponsorship relationship with CSL Behring, Ltd. ending in January 2024.</li> </ul>
Catherine Martin, PharmD, BCOP	Planning Committee Member	No relevant financial disclosures	N/A	N/A
Chelsea Minor, PharmD, BCPS, BCOP	Planning Committee Member	No relevant financial disclosures	N/A	N/A
Danielle Murphy, PharmD, BCOP, BCPS	Planning Committee Member	No relevant financial disclosures	N/A	N/A
Emilie Aschenbrenner, PharmD, BCOP	Faculty	1. Astellas, BMS, Incyte 2. AbbVie, BMS, BeiGene, Incyte, Kite, Sanofi	1. Advisory Board 2. Non-CE Speakers Bureau	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning

Tandem Pharmacy Track at the 2024 Tandem Meetings - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Erika Wass, PharmD, BCOP	Faculty	1. Omeros, Inc.	1. Non-CE Speakers Bureau	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning
Geoff Cuvelier, MD, FRCPC	Faculty	No relevant financial disclosures	N/A	N/A
Heather Tarbox, MPH	TFF Staff	No relevant financial disclosures	N/A	N/A
Jade Kutzke, PharmD	Planning Committee Member	No relevant financial disclosures	N/A	N/A
Jamie Elsner Ziggas, PharmD	Faculty	No relevant financial disclosures	N/A	N/A
Joseph Bubalo, PharmD, BCPS, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Joy Park, PharmD, BCOP	Planning Committee Member	No relevant financial disclosures	N/A	N/A
Jitesh Kawedia, PharmD, PhD	Faculty	1. Acrotech Biopharma	1. Contract Research	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning
Justin Graff, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A

Tandem Pharmacy Track at the 2024 Tandem Meetings - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Justin Tossey, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Katie Gatwood, PharmD, BCOP	Faculty	1. Astellas, BioLineRX  2. Jazz Pharmaceuticals, Kite Pharma, Sanofi  3. AstraZeneca	1. Advisory Board  2. Non-CE Speakers Bureau  3. Contract Research	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning
Kelsey Konrardy, PharmD, BCOP	Planning Committee Chair, Faculty	No relevant financial disclosures	N/A	N/A
Kyra Newman	ASTCT Staff	No relevant financial disclosures	N/A	N/A
Mary McGann, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Margaret Croom Taylor, PharmD	Planning Committee Member	1. Banner Health Medical Writing, LLC, Pharmacy Times CE	1. Non-CE Consulting	The relationship with Pharmacy Times CE was mitigated by ending in April 2023  All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair

Tandem Pharmacy Track at the 2024 Tandem Meetings - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Nicole Daukshus, PharmD, BCOP	Planning Committee Member, Faculty	1. Merck & Co.	1. Stock owner of publicly traded commercial entity	<p>All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair</p> <p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning</p>
Piyanuch Kongtim, MD, PhD	Faculty	1. Eurofins Viracor	1. Contract Research	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning
Rachael Straining, PharmD, BCOP	Planning Committee Member	No relevant financial disclosures	N/A	N/A
Rebecca Gonzalez, PharmD, BCOP	Planning Committee Member, Faculty	No relevant financial disclosures	N/A	N/A
Rebecca Worden, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Sandy On, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Shannon Palmer, PharmD, BCOP	Planning Committee Member	No relevant financial disclosures	N/A	N/A

Tandem Pharmacy Track at the 2024 Tandem Meetings - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Shawn Griffin, PharmD, BCOP	Planning Committee Member, Faculty	No relevant financial disclosures	N/A	N/A
Stephanie Monaco-Cermak, PharmD, BCOP	Planning Committee Member	No relevant financial disclosures	N/A	N/A
Suhani Mehta, PharmD, BCOP	Planning Committee Member	No relevant financial disclosures	N/A	N/A
Susie Long, PharmD	Faculty	No relevant financial disclosures	N/A	N/A
Suzanne Gettys, PharmD, BCOP	Planning Committee Member	No relevant financial disclosures	N/A	N/A
Terri Lynn Shigle, PharmD, BCOP	Faculty	1. Takeda Pharmaceuticals	1. Advisory Board	<p>The relationship with Takeda Pharmaceuticals was mitigated by ending in December 2021</p> <p>All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair</p>
Tiba Al Sagheer, PharmD, BCOP, BCACP	Planning Committee Member	<p>1. Bristol Myers Squibb</p> <p>2. Aptitude Health Meeting</p>	<p>1. Non-CE Consulting</p> <p>2. Other: Educational Meeting Attendee</p>	<p>The following relationships were mitigated by:</p> <ul style="list-style-type: none"> <li>• Bristol Myers Squibb ending in January 2023.</li> <li>• Aptitude Health ending in April 2022.</li> </ul> <p>All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair</p>

Tandem Pharmacy Track at the 2024 Tandem Meetings - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Timothy Porter, PharmD, BCOP	Faculty	1. Medexus Pharmaceuticals	1. Non-CE Consulting	<p>The relationship with Medexus Pharmaceuticals was mitigated by ending in June 2022</p> <p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning</p>
Victoria Jensen, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A